President Obama May Take Up IP Protection Issue During India Visit
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages
You may also be interested in...
Big Pharma Lukewarm To License Compounds From Indian Start-ups, But A Few Could Be Head Turners
MUMBAI - Faced with the bleak prospect of an almost irreversible pipeline drought, Big Pharma has sharpened its focus on identifying differentiated leads from smaller firms - mainly to in-license early-stage compounds - but it appears there are few Indian start-ups with compounds that fit into this strategic goal
Big Pharma Lukewarm To License Compounds From Indian Start-ups, But A Few Could Be Head Turners
MUMBAI - Faced with the bleak prospect of an almost irreversible pipeline drought, Big Pharma has sharpened its focus on identifying differentiated leads from smaller firms - mainly to in-license early-stage compounds - but it appears there are few Indian start-ups with compounds that fit into this strategic goal
PhRMA Meets With Indian Officials To Discuss Compulsory Licensing
Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India's move toward compulsory licensing